Few supplements have generated more research — and more controversy — than omega-3 fatty acids. The headlines have swung wildly over the past decade: first hailed as cardiac cure-alls, then dismissed after several large trials showed no benefit, now being reassessed as researchers understand better which forms, doses, and populations are most likely to respond.
For adults over 50 trying to make an informed decision about omega-3 supplementation, the 2025–2026 research landscape offers meaningful clarity. Here's what the current evidence actually supports.
The Three Main Omega-3s — Why They're Not Interchangeable
Not all omega-3s are equivalent, a nuance that explains much of the apparent contradiction in trial results:
- EPA (eicosapentaenoic acid): The form with the strongest cardiovascular trial evidence. Anti-inflammatory, reduces triglycerides, inhibits platelet aggregation.
- DHA (docosahexaenoic acid): Concentrated in brain tissue; important for cognitive health. Also reduces triglycerides but appears to raise LDL slightly — a complication when evaluating cardiovascular outcomes.
- ALA (alpha-linolenic acid): The plant form (flaxseed, walnuts, chia). Converted to EPA and DHA in the body, but conversion efficiency is poor in adults — typically under 10%.
Most of the conflicting trial results stem from studies that used EPA+DHA combinations at variable doses, or that used ALA as a proxy — when the most compelling data is specifically for high-dose EPA alone.
The REDUCE-IT Trial: The Strongest Evidence to Date
Published in the New England Journal of Medicine in 2018 and with follow-up analyses continuing through 2025, REDUCE-IT remains the landmark trial in this space. It randomized 8,179 adults with elevated triglycerides (150–499 mg/dL) and established cardiovascular disease or diabetes to either high-dose EPA (Vascepa, 4g/day) or placebo.
The result was striking: the EPA group showed a 25% reduction in major adverse cardiovascular events (MACE) — including heart attack, stroke, and cardiovascular death — compared to the mineral oil placebo group. This was a meaningful, clinically significant reduction.
Fish Oil and Insulin Resistance: New 2025 Data
A notable 2025 study reported via ScienceDaily and subsequently published in peer-reviewed form found that fish oil supplementation demonstrated measurable improvements in insulin resistance markers in adults at metabolic risk — independent of triglyceride reduction. This adds a metabolic dimension to omega-3 research beyond its traditionally cardiovascular framing.
The mechanism proposed: EPA reduces inflammatory cytokines (particularly TNF-α and IL-6) that directly impair insulin signaling, improving the cellular response to insulin in skeletal muscle. For adults over 50 who have both cardiovascular risk and blood sugar concerns — a very common combination — this finding suggests omega-3s may support both systems simultaneously.
What Standard Fish Oil Actually Does
Setting aside the high-dose prescription EPA data, here's what the evidence shows for typical OTC fish oil supplementation (1–2g combined EPA+DHA daily):
| Outcome | Evidence Level | Effect Size |
|---|---|---|
| Triglyceride reduction | Strong | 15–30% reduction at 2–4g/day |
| Blood pressure reduction | Moderate | Small (-2 to -3 mmHg systolic) |
| Anti-inflammatory effects | Moderate | Reduced CRP, IL-6 markers |
| MACE reduction (at typical OTC doses) | Mixed/Weak | Most large trials show no significant benefit at 1g/day |
| Cognitive support | Emerging | Promising for DHA in cognitive decline prevention |
| Insulin sensitivity | Emerging (2025) | Modest improvement in high-risk adults |
Dietary Omega-3 vs. Supplements
The evidence for dietary omega-3 from fatty fish is consistently more favorable than supplement trials — likely because fish also provides selenium, vitamin D, and other nutrients that act synergistically. The Mediterranean and traditional Japanese diets, both associated with low cardiovascular mortality, feature 2–4 servings of fatty fish per week.
Fatty fish with the highest omega-3 content per serving:
- Wild-caught salmon: 1,500–2,500mg EPA+DHA per 3oz serving
- Mackerel: 2,200–2,600mg per 3oz serving
- Sardines: 1,300–1,500mg per 3oz serving (canned in water)
- Herring: 1,700–2,000mg per 3oz serving
- Anchovies: 400–600mg per oz (very dense per calorie)
Who Should Consider Omega-3 Supplementation?
Based on the current evidence hierarchy:
- High-priority: Adults with significantly elevated triglycerides (above 200 mg/dL) — the strongest evidence for supplementation, particularly at higher doses. Discuss prescription EPA with your cardiologist.
- Moderate priority: Adults with established cardiovascular disease who don't eat fatty fish regularly — standard fish oil at 1–2g EPA+DHA daily is reasonable.
- Lower priority for supplement form: Adults with normal triglycerides who eat 2+ servings of fatty fish per week likely don't need to supplement.
- Plant-based adults: Algae-derived DHA+EPA supplements are the appropriate alternative to fish oil, providing the actual omega-3s without the ALA conversion problem.
